Tools
Tools
Weeks, Andrew D., Ditai, James, Ononge, Sam, Faragher, Brian, Frye, Laura J., Durocher, Jill, Mirembe, Florence M., Byamugisha, Josaphat, Winikoff, Beverly and Alfirevic, Zarko (2015) 'The MamaMiso study of self-administered misoprostol to prevent bleeding after childbirth in rural Uganda: a community-based, placebo-controlled randomised trial'. BMC Pregnancy and Childbirth, Vol 15, e219.
|
Text
BMC_Preg_Child_15_219.pdf - Published Version Available under License Creative Commons Attribution. Download (1MB) | Preview |
Abstract
Background
600 mcg of oral misoprostol reduces the incidence of postpartum haemorrhage (PPH), but in previous research this medication has been administered by health workers. It is unclear whether it is also safe and effective when self-administered by women.
Methods
This placebo-controlled, double-blind randomised trial enrolled consenting women of at least 34 weeks gestation, recruited over a 2-month period in Mbale District, Eastern Uganda. Participants had their haemoglobin measured antenatally and were given either 600mcg misoprostol or placebo to take home and use immediately after birth in the event of delivery at home. The primary clinical outcome was the incidence of fall in haemoglobin of over 20 % in home births followed-up within 5 days.
Results
748 women were randomised to either misoprostol (374) or placebo (374). Of those enrolled, 57 % delivered at a health facility and 43 % delivered at home. 82 % of all medicine packs were retrieved at postnatal follow-up and 97 % of women delivering at home reported self-administration of the medicine. Two women in the misoprostol group took the study medication antenatally without adverse effects. There was no significant difference between the study groups in the drop of maternal haemoglobin by >20 % (misoprostol 9.4 % vs placebo 7.5 %, risk ratio 1.11, 95 % confidence interval 0.717 to 1.719). There was significantly more fever and shivering in the misoprostol group, but women found the medication highly acceptable.
Conclusions
This study has shown that antenatally distributed, self-administered misoprostol can be appropriately taken by study participants. The rarity of the primary outcome means that a very large sample size would be required to demonstrate clinical effectiveness.
| Item Type: | Article |
|---|---|
| Additional Information: | The electronic version of this article is the complete one and can be found online at: http://www.biomedcentral.com/1471-2393/15/219 |
| Subjects: | WA Public Health > WA 20.5 Research (General) WA Public Health > Health Problems of Special Population Groups > WA 310 Maternal welfare WA Public Health > Health Problems of Special Population Groups > WA 395 Health in developing countries WQ Obstetrics > Childbirth. Prenatal Care > WQ 155 Home childbirth WQ Obstetrics > Pregnancy Complications > WQ 252 Hematologic complications |
| Faculty: Department: | Clinical Sciences & International Health > Clinical Sciences Department |
| Digital Object Identifer (DOI): | https://doi.org/10.1186/s12884-015-0650-9 |
| Depositing User: | Lynn Roberts-Maloney |
| Date Deposited: | 15 Oct 2015 09:50 |
| Last Modified: | 06 Feb 2018 13:10 |
| URI: | https://archive.lstmed.ac.uk/id/eprint/5355 |
Statistics
Actions (login required)
 |
Edit Item |